Prime Medicine (PRME) Cash from Financing Activities (2021 - 2026)

Prime Medicine (PRME) has 6 years of Cash from Financing Activities data on file, last reported at $393000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 93.45% year-over-year to $393000.0; the trailing twelve-month figure through Mar 2026 stood at $145.9 million (up 227.52% YoY), and the FY2025 full-year result was $151.5 million, down 22.65% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $393000.0, down from $562000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $184.1 million in Q4 2022 and bottomed at -$1.3 million in Q1 2022.
• The 5-year median for Cash from Financing Activities is $197000.0 (2025), against an average of $31.2 million.
• The widest annual swing landed in 2023, when Cash from Financing Activities tumbled 99.89%; it then soared 231263.24% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at $184.1 million in 2022, then sank by 99.89% to $194000.0 in 2023, then tumbled by 99.48% to $1000.0 in 2024, then jumped by 56100.0% to $562000.0 in 2025, then tumbled by 30.07% to $393000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $393000.0 (Q1 2026), $562000.0 (Q4 2025), and $144.8 million (Q3 2025), per Business Quant data.

Peer Comparison